Fund · Goldman Sachs MarketBeta International Equity ETF · measured from SEC filings
GSID holdings
GSID reports 894 holdings and behaves like 213.3 equally weighted ones, computed from its SEC Form N-PORT filing for 2026-05-31. The fact sheet publishes the first number; this page computes the second, and traces it across 25 quarters of filings.
Measured concentration
as of 2026-05-31Read this figure with the following in mind
1.5% of net assets is securities-lending cash collateral, excluded from the figure; counted as filed the fund would read 205.6
The figure below is what the filing says, published unchanged. What it may not do is sit beside a plain long-only fund and be read as the same quantity. How comparability is decided.
Computed by this site from the fund's SEC Form N-PORT filing; what the measure does not tell you · every fund in one table · hold it with other funds? X-ray the mix. Pricing: 99.68% at a quoted market price (level 1), 29 issuer countries.
What stands out
as of 2026-05-31GSID's largest investment is ASML Holding NV Eur0.09 at 2.75% of net assets. HSBC Holdings PLC ORD Usd0.50 and Roche Holding AG Chf0.001 follow; the three together are 5.51%. Ten companies are 13.31% of the fund; the other 884 share the rest. Among the 721 equity funds measured here, GSID behaves like 213.3 holdings against a median of 42.4 — 5.0 times the median. Across 25 quarterly filings GSID has held roughly steady since 2020-05-29 (251 then, 213.3 now). Between the 2026-02-28 and 2026-05-31 filings 22 positions were added and 28 dropped; 8.3% of the weight moved. Japan is the largest country at 25.26% of the portfolio, across 29 countries in the filing.
Each sentence is read from the fund's own SEC filing; the class median is computed across the comparable equity funds on this site. Nothing here is a view on the fund.
Every filing since 2020
25Between 2020-05-29 and 2026-05-31, GSID went from behaving like 251 equally weighted positions to 213.3 — 15% fewer, while its top ten went from 12.77% to 13.31% of net assets. Read across the funds on the concentration-over-time table.
| Period | Holdings | Effective | Top 10 | Largest |
|---|---|---|---|---|
| 2026-05-31 | 894 | 213.3 | 13.31% | 2.76% |
| 2026-02-28 | 900 | 223.9 | 13.31% | 2.42% |
| 2025-11-30 | 904 | 235.6 | 12.63% | 1.96% |
| 2025-08-31 | 909 | 245 | 12.08% | 1.47% |
| 2025-05-31 | 898 | 234.7 | 12.66% | 1.65% |
| 2025-02-28 | 902 | 225.2 | 13.58% | 1.62% |
| 2024-11-30 | 899 | 226.9 | 13.45% | 2.02% |
| 2024-08-31 | 900 | 206.7 | 15.06% | 2.48% |
Earlier filings (17 more, back to 2020-05-29)
| Period | Holdings | Effective | Top 10 | Largest |
|---|---|---|---|---|
| 2024-05-31 | 920 | 205.9 | 14.93% | 2.5% |
| 2024-02-29 | 949 | 208.8 | 15.11% | 2.27% |
| 2023-11-30 | 954 | 219.6 | 14.57% | 2.07% |
| 2023-08-31 | 977 | 223.8 | 14.52% | 2.07% |
| 2023-05-31 | 979 | 222.9 | 14.57% | 2.09% |
| 2023-02-28 | 996 | 232.9 | 13.83% | 2.02% |
| 2022-11-30 | 996 | 226.2 | 14.42% | 2.21% |
| 2022-08-31 | 1,032 | 237 | 14.03% | 2.3% |
| 2022-05-31 | 1,034 | 238.4 | 13.73% | 2.2% |
| 2022-02-28 | 1,037 | 246.8 | 13.44% | 2.2% |
| 2021-11-30 | 1,034 | 261.5 | 12.64% | 2% |
| 2021-08-31 | 1,004 | 267.1 | 12.3% | 1.95% |
| 2021-05-28 | 1,014 | 277.2 | 11.75% | 1.91% |
| 2021-02-26 | 990 | 282.6 | 11.32% | 1.82% |
| 2020-11-30 | 992 | 278.1 | 11.5% | 2.11% |
| 2020-08-31 | 982 | 254.2 | 12.65% | 2.47% |
| 2020-05-29 | 983 | 251 | 12.77% | 2.46% |
One row per filed reporting period, newest first, read from EDGAR. Quarterly because that is the public filing cadence. Rows marked * are published but held out of the comparison above; the methodology page says when and why.
As filed, collateral included
1.48% collateralGSID's filing lists 895 positions including 1.48% of net assets in securities-lending cash collateral. Counted as filed the fund reads 205.6 effective holdings with a top ten of 13.73%; on its own investments — the figure above — it reads 213.3 with a top ten of 13.31%. The collateral is matched by a liability and is not a holding the fund chose; since 2026-09-18 every figure on this site sets it aside (methodology). Both numbers are in the data.
Largest positions, as filed
as of 2026-05-31The 15 largest of 894 positions in GSID's Form N-PORT, weight as a share of net assets, securities-lending collateral excluded. Every position, every quarter: GSID.csv.gz.
| # | Position | Weight | Cumulative |
|---|---|---|---|
| 1 | ASML HOLDING NV | 2.76% | 2.8% |
| 2 | HSBC HOLDINGS PLC | 1.45% | 4.2% |
| 3 | ROCHE HOLDING AG | 1.33% | 5.5% |
| 4 | ASTRAZENECA PLC | 1.25% | 6.8% |
| 5 | NOVARTIS AG | 1.23% | 8.0% |
| 6 | NESTLE' SA/AG | 1.18% | 9.2% |
| 7 | SHELL PLC | 1.06% | 10.3% |
| 8 | GOLDMAN SACHS TRUST | 1.03% | 11.3% |
| 9 | SIEMENS AG | 1.02% | 12.3% |
| 10 | BHP GROUP LTD | 1.00% | 13.3% |
| 11 | MITSUBISHI UFJ FINANCIAL GROUP INC | 0.96% | 14.3% |
| 12 | TOYOTA MOTOR CORP | 0.90% | 15.2% |
| 13 | COMMONWEALTH BANK OF AUSTRALIA | 0.89% | 16.1% |
| 14 | SAP SE | 0.83% | 16.9% |
| 15 | BANCO SANTANDER SA | 0.81% | 17.7% |
By country of issuer
as of 2026-05-31Share of GSID's own investments by the issuer country the filer reported (incorporation, not revenue). Each country links to every fund that holds it.
| Country | Share |
|---|---|
| Japan | 25.64% |
| United Kingdom | 13.23% |
| Switzerland | 8.38% |
| Germany | 8.33% |
| France | 7.84% |
| Australia | 7.12% |
| Netherlands° | 6.05% |
| Spain | 3.36% |
Returns the fund reported
2020-05 – 2026-05Monthly total returns from Item B.5 of GSID's own filings, 73 months on record. Not computed here and not from a price feed.
Cross-checked against a series computed separately from prices: median difference 0.43 percentage points over 72 months, which is roughly the distributions. Every month with the filing it came from: GSID.json · all funds.
Who borrows GSID's shares
2026-05-31The fund lends its holdings, and Item B.4.a of the filing names every firm holding them. At 2026-05-31, $14m was out to 10 borrowers, 1.38% of net assets. The largest, J.P. MORGAN SECURITIES PLC, held 35.8% of it.
| Borrower | On loan | Share of the loan |
|---|---|---|
| J.P. MORGAN SECURITIES PLC | $5m | 35.8% |
| Macquarie Bank Limited | $4m | 26.2% |
| CITIGROUP GLOBAL MARKETS LIMITED | $3m | 19.3% |
| BNP PARIBAS SECURITIES CORP | $794,376 | 5.5% |
| UBS AG | $737,596 | 5.1% |
Cash collateral reported against the loan: 1.48% of net assets, 107.1% of the amount lent. That is a floor on the collateral, not the whole of it — collateral the fund does not hold as a position is not in this filing, so a figure under 100% is not evidence of under-collateralisation. How that figure behaves across all funds. Every quarter GSID has filed, with each borrower: GSID.json · all funds.
Since the previous filing
2026-02-28 → 2026-05-31900 positions became 894: 22 added (1.8% of the fund at the later date), 28 dropped (2.6% at the earlier date). Half the sum of all weight changes, a turnover proxy: 8.3%. Positions are matched on identifiers, so a security whose identifier changed shows as one drop and one add. Every filing of GSID compared this way, as a feed: changes.xml · all funds: filings received.
| Largest increases | 2026-02-28 | 2026-05-31 | Largest decreases | 2026-02-28 | 2026-05-31 |
|---|---|---|---|---|---|
| GOLDMAN SACHS TRUST | 0.29% | 1.03% | TOYOTA MOTOR CORP | 1.12% | 0.90% |
| ASML HOLDING NV | 2.42% | 2.76% | NOVARTIS AG | 1.40% | 1.23% |
| SOFTBANK GROUP CORP | 0.42% | 0.75% | UNILEVER PLC | 0.69% | 0.55% |
| MURATA MANUFACTURING COMPANY LTD | 0.19% | 0.45% | ASTRAZENECA PLC | 1.36% | 1.25% |
| INFINEON TECHNOLOGIES AG | 0.31% | 0.55% | MITSUBISHI HEAVY INDUSTRIES LTD | 0.44% | 0.33% |
| KIOXIA HOLDINGS CORP | 0.10% | 0.31% | NATIONAL AUSTRALIA BANK LTD | 0.47% | 0.37% |
New: ROCHE HOLDING AG (1.33%), FURUKAWA ELECTRIC CO LTD (THE) (0.10%), ICE FUTURES U.S. (0.06%), ASCENDIS PHARMA A/S (0.05%), HOCHTIEF AG (0.04%), WISE GROUP PLC (0.04%). Gone: Roche Holding AG (1.46%), NXP Semiconductors NV (0.25%), Amrize Ltd. (0.13%), Ashtead Group PLC (0.13%), AERCAP HOLDINGS NV (0.11%), Toyota Industries Corp. (0.10%).
Asset categories and pricing
as of 2026-05-31| Asset category (as filed) | Share of investments |
|---|---|
| equity EC | 95.80% |
| short-term investment STIV | 2.48% |
| preferred equity EP | 1.65% |
| derivative DE | 0.06% |
99.7% of GSID is carried at a quoted market price (fair-value level 1). Categories and levels are the filer's, from Form N-PORT; what a low level-1 share does and does not mean is in the measure's page.
Derivative exposure and counterparties
as of 2026-05-31A position count cannot describe a fund that uses derivatives, because a swap is filed at its unrealised gain, not its exposure. These are the notionals the fund itself reported, against net assets of $1.05B. Notional of an interest-rate or currency swap is not equity exposure.
Full detail for every fund that files derivatives: leverage.json (CC BY 4.0).
Neighbours by effective holdings, equity funds
10Every measured equity fund lined up by how many holdings it behaves like; these sit either side of GSID (213.3). Same filings, same arithmetic. Position in this list says nothing about which fund is better.
| Fund | Reports | Behaves like | Top ten | As of |
|---|---|---|---|---|
| DBEF Xtrackers MSCI EAFE Hedged Equity ETF | 723 | 206.1 | 13.55% | 2026-05-29 |
| INTF iShares International Equity Factor ETF | 498 | 208.5 | 12.83% | 2026-07-31 |
| IJJ iShares S&P Mid-Cap 400 Value ETF | 303 | 208.8 | 10.09% | 2026-06-30 |
| MDYV State Street(R) SPDR(R) S & P 400(TM) Mid Cap Value ETF | 302 | 209.2 | 10.07% | 2026-06-30 |
| IVOV Vanguard S&P Mid-Cap 400 Value Index Fund | 304 | 210.1 | 10.2% | 2026-05-31 |
| FYC First Trust Small Cap Growth AlphaDEX Fund | 263 | 214.2 | 7.5% | 2026-07-31 |
| VEU Vanguard FTSE All-World Ex-US Index Fund | 3,890 | 216 | 14.39% | 2026-07-31 |
| VYMI Vanguard International High Dividend Yield Index Fund | 1,580 | 217.9 | 13.89% | 2026-07-31 |
| SMIN iShares MSCI India Small-Cap ETF | 475 | 220.2 | 13.3% | 2026-05-31 |
| NUSC Nuveen ESG Small-Cap ETF | 405 | 222.4 | 10.19% | 2026-07-31 |
Essays that examine GSID
0Mentions are detected across the full text of every article, so an appearance may be a passing comparison rather than the subject. Nothing here is a recommendation to buy or sell — see the disclaimer.